Allogene Therapeutics
Allogene Therapeutics raises $325M Series E at $3.9B valuation
Quick Facts
Allogene Therapeutics: Series E Funding Round
Allogene Therapeutics has successfully raised $325M in Series E funding, reaching a valuation of $3.9B.
Company Overview
Allogeneic CAR T therapy developer
Funding Details
The Series E round was led by TPG, with participation from Gilead Sciences, Pfizer, Frazier Healthcare Partners, University of California.
Company Information
- Headquarters: 210 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2017
- Employees: 700+
- Category: Biotech
Investment
Allogene Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- TPG: Verified investor in Series E
- Gilead Sciences: Verified investor in Series E
- Pfizer: Verified investor in Series E
- Frazier Healthcare Partners: Verified investor in Series E
- University of California: Verified investor in Series E
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...